UNSPSC 51431803: Methyldopa

This classification denotes a dopamine agonist and antihypertensive agent with the molecular formula 2C10H13NO4.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56LH93261Y, chemically known as 3,4-dihydroxy-2-methylphenylalanine but generally known as methyldopa, which bears US NIH Compound Identifier 4138. European Medicines Agency schedules Methyldopa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08867MIG.

UNSPSC 51431803 Methyldopa is a Commodity code representing specific pharmaceutical products procured by state and local health systems, emergency medical services, and pharmacy benefit programs. State and local governments buy methyldopa and related antihypertensive medications through three primary channels: emergency medical services supply contracts for advanced life support medication kits, cooperative purchasing agreements for generic pharmaceutical inventories serving state and local healthcare facilities, and emerging direct-to-manufacturer pharmacy programs operated by state health agencies. The issuing bodies include city fire rescue departments, state health and human services agencies, and multistate cooperative purchasing consortiums representing state and local members across multiple jurisdictions.

Recent activity spans Florida, Minnesota, and Texas. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) posted April 24, 2026, for Advanced Life Support Medications for Tampa Fire Rescue, with a response deadline of April 8, 2026 and estimated contract value of $40,000, requiring supply of labetalol, epinephrine, adenosine, and diltiazem with nine-month minimum expiration dates and ten-calendar-day delivery, with a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers with a response deadline of March 26, 2026, establishing two-year contracts effective July 1, 2026, with price competitiveness weighted at 75 percent of evaluation criteria. The Texas Health and Human Services Commission issued an RFI (HHS0017013) posted April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs as a precursor to formal solicitation.